Skip to main content
Premium Trial:

Request an Annual Quote

Ambry to Use Agilent SureSelect for Exome Sequencing Services


Agilent Technologies and Ambry Genetics have signed an agreement under which Ambry will use Agilent's SureSelect Target Enrichment System for exome sequencing services, the companies said last week.

Ardy Arianpour, vice president of business development at Ambry, said in a statement that the company is using SureSelect to offer whole-exome capture services for "cancer markers, drug response, and Mendelian disease gene discovery."

Ambry last month began offering clinical exome sequencing for patients with undiagnosed or difficult-to-diagnose genetic disorders (CSN 10/5/2011).